Fifteen Minute Test May Save 15% or More on Rosacea Treatment

Evan Darwin, Jessica Cervantes, Hadar Lev-Tov

Research output: Contribution to journalArticle

Abstract

Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health care system both time and money. J Drugs Dermatol. 2018;17(5):692-693.

Original languageEnglish (US)
Pages (from-to)692-693
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume17
Issue number6
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Rosacea
Oxymetazoline
Patient Selection
Sulfates
Patient Care
Delivery of Health Care
Skin
Therapeutics
Pharmaceutical Preparations
Population
Brimonidine Tartrate

ASJC Scopus subject areas

  • Dermatology

Cite this

Fifteen Minute Test May Save 15% or More on Rosacea Treatment. / Darwin, Evan; Cervantes, Jessica; Lev-Tov, Hadar.

In: Journal of drugs in dermatology : JDD, Vol. 17, No. 6, 01.06.2018, p. 692-693.

Research output: Contribution to journalArticle

Darwin, Evan ; Cervantes, Jessica ; Lev-Tov, Hadar. / Fifteen Minute Test May Save 15% or More on Rosacea Treatment. In: Journal of drugs in dermatology : JDD. 2018 ; Vol. 17, No. 6. pp. 692-693.
@article{9b0ba41ee902405e907965e9ad361cc5,
title = "Fifteen Minute Test May Save 15{\%} or More on Rosacea Treatment",
abstract = "Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health care system both time and money. J Drugs Dermatol. 2018;17(5):692-693.",
author = "Evan Darwin and Jessica Cervantes and Hadar Lev-Tov",
year = "2018",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "692--693",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Fifteen Minute Test May Save 15% or More on Rosacea Treatment

AU - Darwin, Evan

AU - Cervantes, Jessica

AU - Lev-Tov, Hadar

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health care system both time and money. J Drugs Dermatol. 2018;17(5):692-693.

AB - Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health care system both time and money. J Drugs Dermatol. 2018;17(5):692-693.

UR - http://www.scopus.com/inward/record.url?scp=85054896901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054896901&partnerID=8YFLogxK

M3 - Article

C2 - 29879260

AN - SCOPUS:85054896901

VL - 17

SP - 692

EP - 693

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -